Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Core Insights - Armata Pharmaceuticals is focused on developing high-purity, pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections [1][6] - The company is presenting its phage development programs at the 2024 Military Health System Research Symposium, highlighting two candidates: inhaled AP-PA02 for Pseudomonas aeruginosa bronchiectasis and intravenous AP-SA02 for Staphylococcus aureus bacteremia [1][4] Clinical Development - The Phase 1b/2a diSArm study for intravenous AP-SA02 is 80% enrolled, with completion expected by the end of 2024 [2] - The clinical development of AP-SA02 is supported by a $21.6 million grant from the Department of Defense [2] - Preliminary data indicates that both intravenous AP-SA02 and inhaled AP-PA02 have been well tolerated, with promising pharmacokinetic results suggesting potential clinical benefits [4] Future Plans - The company aims to advance both AP-SA02 and AP-PA02 into pivotal Phase 3 trials in 2025, with the goal of introducing a new class of anti-infectives [3][4] - The poster presentation at MHSRS will discuss the ongoing clinical trials and their implications for treating difficult-to-treat infections [4][5] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, utilizing proprietary technology [6] - The company is developing a pipeline of natural and synthetic phage candidates targeting various pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus [6]